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Abstract 
Macrophage activation syndrome (MAS) is a potentially life-threatening 
complication of rheumatic diseases such as systemic juvenile idiopathic 
arthritis (sJIA) and systemic lupus erythematosus.  It is often considered a 
type of secondary haemophagocytic lymphohistiocytosis (HLH) and results 
from over-activation of T lymphocytes and macrophages leading to a 
“cytokine storm”.  Characteristic features are persistent fever, 
lymphadenopathy, hepatosplenomegaly, cytopenias (anaemia, leucopenia, 
thrombocytopenia), raised C-reactive protein, falling erythrocyte 
sedimentation rate, hypofibrinogenaemia, transaminitis, hypertriglyceridaemia 
and extreme hyperferritinaemia often associated with multi-organ impairment.  
Key to its management is early recognition of MAS which may be difficult due 
to similarity to systemic sepsis or flares of the underlying rheumatic disease.  
To aid with this process, criteria for the diagnosis of MAS in patients with sJIA 
derived by international consensus have been published.  Although bone 
marrow biopsy showing haemophagocytosis is strongly supportive it is not 
essential for diagnosis.  Together with appropriate supportive care, first-line 
treatment is high-dose intravenous corticosteroids with ciclosporin or 
intravenous immunoglobulin (IVIg) added if there is not initial response.  
Although etoposide is used by haematologists in treatment of HLH, there are 
concerns regarding organ toxicity and bone marrow suppression which weigh 
against its use in initial management of MAS.  With increasing understanding 
of the pathogenesis of MAS, use of drugs targeting specific cytokines has 
been reported in case series.  The relatively rapid effectiveness of anakinra, a 
recombinant IL-1 receptor antagonist, has been documented.  Further studies 
of this and other biologic agents are required to identify the most effective and 
safest treatment option for refractory MAS.
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Introduction 
Macrophage activation syndrome (MAS) is a serious complication of 
rheumatic diseases, with mortality rates reported to be as high as 8-22% (1, 
2).  Excessive T cell and macrophage activation and proliferation leads to 
hypercytokinaemia and haemophagocytosis.  This activation cascade can 
lead to an overwhelming, and potentially fatal, multisystem inflammatory 
response. 
MAS belongs to a group of disorders known as haemophagocytic 
lymphohistiocytosis (HLH).  Primary, or familial, HLH includes patients with a 
variety of rare, autosomal recessive immune defects.  These patients present 
early in life and are unlikely to survive without haematopoietic stem cell 
transplantation.   Secondary HLH includes patients, usually older children, in 
whom the condition is association with a trigger such as an identifiable 
infectious episode or malignancy.  MAS has close similarity with secondary 
HLH and is classified by some as a type of secondary HLH occurring 
specifically in the context of rheumatic disease (3). 
 
The purpose of this article is to highlight the clinical features of MAS which 
should increase the index of suspicion for the condition, the laboratory tests 
which help support a diagnosis and an approach to managing patients with 
MAS. 
 
Epidemiology 
MAS is seen in a variety of different rheumatic diseases in adults and 
children, but is most commonly reported in systemic juvenile idiopathic 
arthritis (sJIA) and its adult equivalent, adult-onset Still’s disease.  Overt MAS 
is seen in approximately 7-13% of patients with sJIA (2, 4, 5) and a more 
occult/subclinical phenotype is seen in up to a third of patients with active sJIA 
(4, 6).  After sJIA, MAS is most frequently encountered in systemic lupus 
erythematosus (SLE) (7, 8) and Kawasaki disease (8-10) but it has also been 
reported in the context of polyarticular JIA (1, 11, 12), juvenile 
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dermatomyositis (13), antiphospholipid syndrome (14) and mixed connective 
tissue disease (14). 
 
Aetiology 
Whilst the precise aetiology of MAS is unknown, the condition is thought to be 
due to abnormal immune regulation giving rise to an exaggerated 
inflammatory response.  MAS can be triggered by a flare of an existing 
rheumatic disease or can be the presenting feature of the new rheumatic 
diagnosis.  Avcin et al reported three patients who presented with MAS as the 
initial presentation of SLE, sJIA and Kawasaki disease (8). 
In common with other HLH conditions, infections and medications have been 
identified as triggers for MAS.  Infection is thought to be the trigger for MAS in 
approximately half of patients; these include both viral infections (typically 
Epstein-Barr virus [EBV], cytomegalovirus and herpes viruses) and bacterial 
infections (12, 15).  Recently, reactive HLH has been described in association 
with Dengue and Ebola virus infections (16, 17).  A systematic review of 
reported cases of HLH in India found that in 44% of 93 children infection was 
the trigger while connective tissue disease was the cause in 18%.(18)  
Amongst the 41 patients with infectious aetiology, viruses (such as EBV and 
Dengue) were the cause in 56% and tropical infectious agents in 32%.  In 
addition, a diverse range of drugs have been implicated in the development of 
MAS, including biological therapies (19, 20).   
 
Clinical Features 
MAS can affect many organ systems (see Table 1).  Clinical findings can 
evolve rapidly causing patients to become acutely, significantly unwell.  
Typical features of MAS include unremitting high fevers, altered mental state, 
lymphadenopathy and hepatosplenomegaly.  Patients develop a 
haemorrhagic, disseminated intravascular coagulation (DIC)-like syndrome 
causing skin rashes ranging from mild petechiae to purpura and extensive 
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ecchymoses (21).  As the disease progresses patients may also bleed from 
other sites (e.g. respiratory and gastrointestinal tract).  Patients become 
encephalopathic with a number of CNS abnormalities.  Renal involvement has 
been reported in a number of series (2, 22) and patients with renal 
dysfunction have a substantially higher risk of mortality (2).  Respiratory 
manifestations of MAS include pulmonary infiltrates and acute respiratory 
distress syndrome (11, 12). 
 
Laboratory features 
There are a number of features, highly suggestive of MAS, which are found 
on laboratory tests.  One of the earliest features is a fall in two of the three 
blood cell lines (leucocytes, erythrocytes and platelets), with the drop in 
platelets tending to occur first (21).  This drop in cell counts is thought to be 
due to increased cell destruction by phagocytosis and consumption due to 
inflammation, rather than bone marrow suppression; bone marrow aspirates 
from MAS patients show significant hypercellularity and normal 
megakaryocytes (23) .  Changes in inflammatory parameters are also typical 
in MAS. C-reactive protein (CRP) remains high whereas paradoxically 
erythrocyte sedimentation rate (ESR) drops considerably (possibly due to 
reduced fibrinogen).   Ferritin is seen at extremely high levels in MAS patients 
and is a distinctive feature; a ferritin value of >10,000 ng/mL has been shown 
to be highly sensitive and specific for a diagnosis of HLH in children (24).  
Extreme hyperferritinaemia is thought to be secondary to excessive 
erythrophagocytosis and sequestration of resultant free iron. 
 
Table 1: Clinical and laboratory features of MAS 
System Clinical features Laboratory features 
General Fevers Fall in ESR 
Raised CRP 
Elevated sIL-2Ra 
Haematological Coagulopathy 
Petechiae, 
Extreme 
hyperferritinaemia  
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purpura, 
ecchymoses 
Epistaxis 
 
Leucopenia 
Anaemia 
Thrombocytopenia 
Haemophagocytosis 
and hypercellularity on 
bone marrow 
aspiration 
Central nervous system Altered mental 
state 
Seizures 
Encephalopathy 
Coma 
CSF pleiocytosis 
 
Gastrointestinal Haematemesis 
Rectal bleeding 
Liver dysfunction 
Transaminitis 
Mildly elevated 
bilirubin 
Hypoalbuminaemia 
Normal or mildly 
raised ammonia 
Elevated triglycerides 
Renal - Abnormal renal 
function 
Respiratory ARD 
Pulmonary 
infiltrates 
- 
Legend: ARD, acute respiratory distress; CRP, C-reactive protein; CSF, 
cerebrospinal fluid; ESR, erythrocyte sedimentation rate; sIL-2Ra, soluble 
interleukin-2 receptor alpha chain (also known as sCD25). 
Diagnosis 
Early diagnosis and initiation of treatment is paramount in MAS given the 
severity of the condition. However, clinical features of MAS show considerable 
overlap with the underlying rheumatic condition, making early diagnosis 
difficult. Thus, it is the results of laboratory tests which heavily support the 
diagnosis of MAS in patients with clinical features suggestive of the condition. 
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For example, in juvenile SLE patients, hyperferritinaemia is a key 
discriminator between a SLE flare and SLE-induced MAS as features such as 
fever, cytopenias and liver dysfunction are common to both.  Similarly, in 
patients with sJIA, an absence of arthritis and serositis, a haemorrhagic rather 
than maculopapular rash and a sudden drop in ESR are highly suggestive of 
MAS (see Table 2). 
Table 2: Comparison of clinical and laboratory features of systemic juvenile 
idiopathic arthritis (sJIA) and macrophage activation syndrome (MAS), 
reproduced from (21) with publisher’s permission 
 sJIA MAS 
Fever pattern Quotidian Unremitting 
Rash Evanescent, 
maculopapular 
Petechial or purpuric 
Hepatosplenomegaly + + 
Lymphadenopathy + + 
Arthritis + - 
Serositis + - 
Encephalopathy ± + 
WCC and neutrophil 
count 
  
Haemoglobin  Normal or   
Platelets   
ESR  Normal or sudden  
Bilirubin Normal Normal or  
ALT/AST Normal or   
PT Normal  
PTT Normal  
D-dimers   
Fibrinogen   
Ferritin Normal or   
 8 
sIL-2Ra Normal or   
CD163 Normal or   
Legend: ALT, alanine aminotransferase; AST, aspartate aminotransferase; 
ESR, erythrocyte sedimentation rate; MAS, macrophage activation syndrome; 
PT, prothrombin time; PTT, partial thromboplastin time; sIL-2Ra, soluble 
interleukin-2 receptor alpha chain (also known as sCD25); sJIA, systemic 
juvenile idiopathic arthritis; WCC, white cell count 
 
Whilst diagnostic and therapeutic guidelines exist for HLH (25), there are no 
such consensus diagnostic criteria for MAS thus clinical vigilance with 
attention to the features above is paramount, particularly in rheumatology 
patients who are at increased risk of MAS.  Whilst MAS is considered by 
some to be a form of secondary HLH, when the HLH criteria are applied to 
patients with MAS and sJIA they are highly specific but have low sensitivity 
(26).  In addition, the overlap in clinical features between HLH diagnostic 
guidelines and those seen the rheumatic conditions underlying MAS limit their 
usefulness in the paediatric rheumatology population.  As a result, preliminary 
guidelines for diagnosing MAS in sJIA patients were drafted (27) which 
showed improved sensitivity for diagnosing MAS in these patients (26).  Work 
is ongoing to optimise the diagnostic criteria for MAS to produce consensus 
guidelines for use in patients with rheumatic disease (28).  The key features of 
MAS identified from this work are: 
1. Falling platelet count 
2. Hyperferritinaemia 
3. Haemophagocytosis on bone marrow biopsy 
4. Raised liver enzymes 
5. Falling leucocyte count 
6. Persistent, continuous fever of >38oC 
7. Falling ESR 
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8. Hypofibrinogenaemia 
9. Hypertriglyceridaemia 
After a consensus conference of international experts on MAS, the following 
definition was agreed upon: “A febrile patient with known or suspected sJIA is 
classified as having MAS if the patient has: ferritin >684 ng/mL and at least 2 
of the following 4 laboratory abnormalities: platelets ≤ 181 x 109 /L, aspartate 
aminotransferase (AST) > 48 U/L, triglycerides > 156 mg/dL, and fibrinogen ≤ 
360 mg/dL” (29). 
 
A diagnosis of MAS can be confirmed by the presence of haemophagocytosis 
on bone marrow biopsy but haemophagocytosis can be variable, particularly 
early in the disease and is subject to sampling error.  A multinational study of 
362 patients with MAS complicating sJIA reported that only 60.7% of patients 
whose bone marrow was examined showed haemophagocytosis (30).  In the 
negative cases, serial bone marrow biopsies may be required to demonstrate 
haemophagocytosis although this is not essential for a diagnosis of MAS to be 
made.  Recent work has shown that staining bone marrow samples with anti-
CD163 antibody demonstrates a massive expansion of highly activated 
histiocytes in MAS patients and has led to the demonstration of 
haemophagocytosis in bone marrow samples reported to be normal using 
standard staining techniques.  Thus anti-CD163 antibody can add to the 
diagnostic yield (4), particularly in patients early in the disease course where 
haemophagocytosis is more limited or with occult/subclinical disease.   
Soluble IL2-Ra and soluble CD163 in serum have also been suggested as 
diagnostic markers as they are thought to reflect T cell and macrophage 
activation (6), however at the current time these tests are only available in 
specialist laboratories. 
 
Management 
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Central to the management of MAS is its early recognition, which requires 
increased awareness of the condition amongst the medical community, 
followed by prompt treatment.  In its early stages, it may mimic infection or 
flares of the underlying rheumatic disease, such as sJIA or SLE.  The clinical 
features and investigations described above assist in the differential 
diagnosis. 
MAS is a potentially life-threatening disease and in all cases appropriate 
resuscitation and supportive care is required.  A multicentre study of MAS in 
sJIA reported that 35% of 235 patients required admission to the intensive 
care unit (ICU) (30).  No randomised controlled trials (RCTs) of targeted 
treatment of MAS have been performed therefore evidence derives from case 
series and individual case reports.  The commonest initial treatment is 
corticosteroids commencing with high-dose intravenous (IV) 
methylprednisolone (30mg/kg, maximum 1000mg, daily for 3 days) followed 
by oral prednisolone 2-3mg/kg/day in divided doses (31).  This controls 
disease in almost half of patients (21).  If not immediately effective, ciclosporin 
(2-7mg/kg/day IV) is often used as a second line agent with reports of its 
effectiveness from several case series (11, 32).  Intravenous immunoglobulin 
(IVIg, 2g/kg in a single dose) can be considered, particularly if the exclusion of 
sepsis is difficult in a ill child with MAS (33). 
If MAS remains active despite the above treatments, etoposide may be 
considered as part of the HLH-2004 treatment protocol (25).  It is used more 
frequently as first-line treatment by haematologists/oncologists for other forms 
of secondary HLH, however is felt by rheumatologists to be too aggressive for 
initial treatment of sJIA-associated MAS (34).  Particular concern surrounds 
toxicity of etoposide which is metabolised by the liver and excreted by the 
kidneys, both organ systems which may be impaired in severe MAS.  Side 
effects such as bone marrow suppression and overwhelming sepsis may be 
reduced by using fewer, lower doses of etoposide than the HLH-2004 protocol 
suggests but there are no studies examining this.  An alternative to etoposide, 
particularly in cases of MAS with renal or hepatic involvement, is anti-
thymocyte globulin (ATG) (35).  Although well-tolerated in case reports, it 
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frequently causes infusion reactions in the context of haematopoietic stem cell 
transplantation.   
During the past decade, biologic agents have been given to treat steroid- and 
ciclosporin-refractory MAS and were used in 15.2% of 341 patients in a 
retrospective multicentre study (30).  Tumour necrosis factor (TNF) inhibitors 
have shown efficacy in some cases, however there have been reports of MAS 
developing in patients while on these drugs (20, 21).  Key cytokines in the 
pathogenesis of sJIA are IL-1 and IL-6 (31).  Since MAS often coincides with 
flares of sJIA, drugs targeting these cytokines have been employed in 
treatment.  Several case reports and series have shown clear and rapid 
benefit from anakinra, a recombinant IL-1 receptor antagonist, when used in 
addition to steroids, ciclosporin or IVIg (36, 37).  A series of 12 patients with 
MAS who had not been controlled by corticosteroids and other 
immunosuppressants (IVIg [n= 9], ciclosporin [n=10], etoposide [n=2], 
etanercept [n=1]) were given subcutaneous anakinra (2mg/kg/day, maximum 
100mg) (37).  All patients achieved remission of MAS within a median of 13 
(range 2-19) days after starting anakinra and remained in remission at median 
of 22 months’ follow-up.  This study reported that no side effects of anakinra 
were noted.  However, other studies have documented new-onset MAS in 
sJIA patients while being treated with anakinra (38, 39).  Canakinumab, an 
anti-IL-1β monoclonal antibody, has not been shown to prevent MAS despite 
maintaining control of sJIA.(40) 
Tocilizumab, a monoclonal antibody against the IL-6 receptor, has shown 
efficacy in treatment of sJIA in RCTs.(41, 42)  There is one report of its use 
for treatment of MAS in adult-onset Still’s disease.(43)  However, of concern, 
one RCT of tocilizumab in sJIA reported 1.5 new MAS cases per 100 patient-
years of treatment.(41)  Another study highlighted that tocilizumab may mask 
changes in laboratory values in sJIA patients who developed MAS: the CRP 
remained normal and rise in ferritin was moderate.(44)  Therefore, caution 
must be used when reviewing sJIA patients treated with tocilizumab to ensure 
that the diagnosis of MAS is not missed. 
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In cases of MAS triggered by Epstein-Barr virus (EBV) infection, depletion of 
B lymphocytes using rituximab, a monoclonal antibody against CD20 has 
been shown to be effective.(45)  The body of evidence supporting use of 
biologics for MAS after failure of other immunomodulatory treatment is 
growing: Minoia et al reported 52 patients receiving these agents of whom 33 
were given anakinra.(30) 
Future therapies for MAS will need to focus on pathways involved in triggering 
the “cytokine storm”.  One potential target is interferon-gamma (IFNγ), which 
is thought to be involved in pathogenesis of both familial and secondary forms 
of HLH, and clinical trials of drugs blocking IFNγ are in progress.(31) 
 
Summary 
Macrophage activation syndrome is a potentially life-threatening complication 
of a range of rheumatic conditions in children.  Key features are unremitting 
fever, lymphadenopathy, hepatosplenomegaly, cytopenias and marked 
hyperferritinaemia.  Central to its management is early recognition and rapid 
treatment.  Consensus criteria for diagnosis of MAS in the context of sJIA will 
assist with this process.  First-line treatment involves multi-system supportive 
care and high-dose corticosteroids with addition of ciclosporin if there is not a 
rapid response to initial therapy.  For refractory cases, etoposide or anti-
thymocyte globulin have been used, although the biologic agent anakinra is 
increasingly being reported as the next step after steroids and ciclosporin.
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